An international, chemistry-based CRO, on a mission to accelerate the discovery and development of high-quality drugs.
LCC provides leading scientific organizations around the world with access to chirally-pure compounds that play their part in small molecule drug discovery.
BioTools has partnered with LCC to provide definitive determinations of Absolute Configuration by VCD. LCC has over thousand of chirally-pure compounds in their catalog in addition to their customer specific custom synthesis novel materials. As we progress with VCD determinations, the LCC’s CoAs (certificate Of Analysis) will now feature Absolute Configuration by VCD.
BioTools and Liverpool ChiroChem announce a collaboration aimed at accelerating the discovery of novel, stereo-defined, enantioenriched compounds.
Gaussian, Inc. develops, licenses, and supports the Gaussian and GaussView computational chemistry software. These state-of-the-art packages allow you to model complex chemical reactions and substances at the highest available levels of accuracy. They are used by chemists, chemical engineers, materials scientists, and other researchers worldwide.
GlycoMIP: An NSF Materials Innovation Platform, or GlycoMIP for short, is an NSF-funded national user facility and multidisciplinary research program that addresses scientific and technological bottlenecks in glycomaterials research.
Operated jointly by Virginia Tech and the University of Georgia, the GlycoMIP user facility will offer capabilities and services in
- glycan synthesis—the facility will house two automated glycan synthesizers
- glycomaterial structure determination—through state-of-the-art mass spectrometry and nuclear magnetic resonance spectroscopy instruments
- computer modeling of glycomaterials—accessible remotely through a unique virtual user facility
- molecular interaction measurements — the facility will offer a range of interaction analysis methods
- solution-state structure determination — through complementary vibrational optical activity methods
Chiral Technologies, a subsidiary of DAICEL CORPORATION, serves pharmaceutical and other life science industries and offers the largest portfolio of chiral stationary phases (CSPs) and analytical and preparative chiral columns for the separation of racemic mixtures into single enantiomers.
Regis Technologies, Inc. partners with pharmaceutical and biotechnology companies to help expedite their drug candidates to market. Regis offers a full range of services to support the development of our clients’ lead molecules from preclinical and clinical API needs through commercialization, including process research and development, solid state chemistry, analytical development and stability services, and GMP API manufacturing. Regis has commercial products approved around the world and has over a decade of FDA inspections without receiving a Form 483.
In addition to our extensive API development and manufacturing, we also offer an innovative line of proprietary chromatography products sold throughout the world. Regis is privately owned and operated and has been in business in the Chicago area since 1956.